Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Angelini Pharma

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cenobamate

            Therapeutic Area: Neurology Product Name: Xcopri

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Arvelle Therapeutics

            Deal Size: $960.0 million Upfront Cash: $960.0 million

            Deal Type: Acquisition January 04, 2021

            Details:

            Following Angelini Pharma’s acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lurasidone HCl

            Therapeutic Area: Psychiatry/Psychology Product Name: Latuda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sunovion Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 12, 2020

            Details:

            Latuda becomes the first 2nd generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age. In addition to the new indication, Latuda was also granted an additional year of marketing protection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gaboxadol

            Therapeutic Area: Genetic Disease Product Name: OV101

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Ovid Therapeutics

            Deal Size: $232.0 million Upfront Cash: $20.0 million

            Deal Type: Licensing Agreement July 13, 2020

            Details:

            Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 for the treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Kingdom and Russia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Camphor,Capsicum oleoresin,Menthol

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: GlaxoSmithKline

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 10, 2020

            Details:

            The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its International presence.